A O
fusion O
complementary O
DNA O
in O
the O
T B
cell I
line I
HSB-2 I
elucidates O
a O
provocative O
mechanism O
for O
the O
disruption O
of O
the O
putative O
hematopoietic O
transcription O
factor O
SCL O
. O

Two O
other O
T B
cell I
lines I
, O
CEM B
and O
RPMI B
8402 I
, O
have O
essentially O
identical O
deletions O
. O

Four O
specific O
protein-DNA O
complexes O
were O
detected O
after O
incubation O
of O
nuclear O
extracts O
( O
NE O
) O
from O
T3-responsive B
pituitary I
( I
GH3 I
) I
cells I
with O
a O
TREp-containing O
DNA O
fragment O
. O

Incubation O
of O
each O
of O
the O
TRs O
with O
NE O
from O
COS-7 B
cells I
, O
which O
do O
not O
possess O
sufficient O
endogenous O
TRs O
to O
mediate O
T3-responses O
, O
resulted O
in O
formation O
of O
a O
new O
, O
more O
greatly O
shifted O
complex O
. O

A O
similar O
, O
heat O
labile O
activity O
which O
altered O
mobility O
of O
the O
TR O
: O
TRE O
complex O
was O
also O
present O
in O
NE O
from O
T3-unresponsive B
JEG-3 I
cells I
. O

Tumor O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
mRNA O
production O
was O
analyzed O
by O
polymerase O
chain O
reaction O
amplification O
in O
monocytic B
U937 I
cells I
and O
in O
a O
chronically B
HIV I
infected I
U937 I
cell I
line I
( O
U9-IIIB B
) O
. O

TNF-alpha O
RNA O
was O
undetectable O
in O
U937 B
cells I
, O
whereas O
a O
low O
constitutive O
level O
was O
detected O
in O
U9-IIIB B
cells I
. O

Paramyxovirus O
infection O
induced O
a O
5- O
to O
10-fold O
increase O
in O
the O
steady-state O
level O
of O
TNF-alpha O
RNA O
in O
U9-IIIB B
cells I
compared O
with O
U937 B
cells I
, O
suggesting O
that O
HIV-infected B
monocytic I
cells I
produced O
higher O
levels O
of O
TNF-alpha O
than O
did O
normal O
cells O
after O
a O
secondary O
virus O
infection O
. O

In O
U937 B
and I
Jurkat I
T I
lymphoid I
cells I
, O
the O
inducibility O
of O
the O
different O
hybrid O
promoters O
by O
TNF-alpha O
or O
phorbol O
ester O
varied O
in O
a O
cell O
type- O
and O
promoter O
context-specific O
manner O
; O
the O
levels O
of O
gene O
activity O
of O
NF-kappa O
B-containing O
plasmids O
correlated O
directly O
with O
induction O
of O
NF-kappa O
B O
DNA-binding O
activity O
. O

This O
level O
of O
NF-kappa O
B O
-independent O
activity O
appears O
to O
be O
sufficient O
for O
virus O
multiplication O
, O
since O
TNF-alpha O
treatment O
had O
no O
effect O
on O
the O
kinetics O
of O
de O
novo O
HIV O
type O
1 O
( O
HIV-1 O
) O
infection O
and O
viral O
RNA O
production O
in O
U937 B
cells I
. O

However O
, O
in O
Jurkat B
cells I
, O
TNF-alpha O
dramatically O
enhanced O
the O
spread O
of O
HIV-1 O
through O
the O
cell O
population O
and O
increased O
viral O
RNA O
synthesis O
, O
indicating O
that O
in O
T O
cells O
HIV-1 O
multiplication O
was O
stimulated O
by O
TNF-alpha O
treatment O
. O

In O
order O
to O
characterize O
the O
function O
of O
cis-acting O
elements O
, O
we O
have O
developed O
an O
in O
vitro O
system O
in O
which O
a O
DRA O
promoter O
construct O
is O
transcribed O
more O
efficiently O
in O
extracts O
from O
B O
cells O
than O
in O
extracts O
from O
class B
II-negative I
HeLa I
cells I
. O

Lipopolysaccharide O
( O
LPS O
) O
potently O
stimulates O
human O
immunodeficiency O
virus O
type O
1-long O
terminal O
repeat O
( O
HIV-1-LTR O
) O
CAT O
constructs O
transfected O
into O
monocyte/macrophage-like B
cell I
lines I
but O
not O
a O
T B
cell I
line I
. O

Electrophoretic O
mobility O
shift O
assays O
demonstrate O
that O
LPS O
induces O
a O
DNA O
binding O
activity O
indistinguishable O
from O
NF-kappa O
B O
in O
U937 B
and O
THP-1 B
cells I
. O

LPS O
is O
also O
shown O
to O
dramatically O
increase O
HIV-1 O
production O
from O
a O
chronically B
infected I
monocyte/macrophage-like I
cloned I
cell I
line I
, O
U1 B
, O
which O
produces O
very O
low O
levels O
of O
HIV-1 O
at O
baseline O
. O

LPS O
is O
not O
able O
to O
induce O
HIV-1 O
production O
in O
a O
cloned O
T B
cell I
line I
. O

Megakaryocytic B
and I
erythrocytic I
lineages I
share O
specific O
transcription O
factors O
. O

A O
closely O
related O
( O
if O
not O
identical O
) O
protein O
is O
found O
in O
both O
a O
human B
megakaryocytic I
cell I
line I
and O
purified B
human I
megakaryocytes I
; O
it O
binds O
to O
promoter O
regions O
of O
two O
megakaryocytic-specific O
genes O
. O

The O
binding O
sites O
and O
partial O
proteolysis O
profile O
of O
this O
protein O
are O
indistinguishable O
from O
those O
of O
the O
erythroid O
protein O
; O
also O
, O
NF-E1 O
messenger O
RNA O
is O
the O
same O
size O
in O
both O
the O
megakaryocytic B
and I
erythroid I
cell I
lines I
. O

We O
also O
find O
that O
NF-E2 O
, O
another O
trans-acting O
factor O
of O
the O
erythrocytic O
lineage O
, O
is O
present O
in O
megakaryocytes B
. O

Our O
data O
strengthen O
the O
idea O
of O
a O
close O
association O
between O
the O
erythrocytic B
and I
the I
megakaryocytic I
lineages I
and O
could O
also O
explain O
the O
expression O
of O
markers O
specific O
to O
the O
erythrocytic O
and O
megakaryocytic O
lineages O
in O
most O
erythroblastic B
and I
megakaryoblastic I
permanent I
cell I
lines I
. O

Transcriptional O
down-regulation O
of O
c-myc O
expression O
by O
protein O
synthesis-dependent O
and O
-independent O
pathways O
in O
a O
human B
T I
lymphoblastic I
tumor I
cell I
line I
. O

We O
show O
that O
in O
the O
human B
T I
lymphoblastic I
tumor I
cell I
line I
Molt4 O
c-myc O
mRNA O
and O
protein O
expression O
is O
down-regulated O
after O
exposure O
to O
dimethyl O
sulfoxide O
, O
to O
phorbol O
myristate O
acetate O
, O
or O
to O
the O
calcium O
ionophore O
A23187 O
, O
which O
raises O
the O
intracellular O
calcium O
concentration O
. O

Cultured B
MCF-7 I
cells I
, O
derived O
from O
a O
pleural O
effusion O
of O
a O
breast O
cancer O
patient O
, O
known O
to O
contain O
high O
levels O
of O
ER O
were O
used O
as O
a O
positive O
control O
( O
40-48 O
% O
ER O
positive O
cells O
by O
immunocytochemistry O
; O
200 O
fmol/mg O
protein O
by O
EIA O
) O
. O

Type-II O
estrogen O
binding O
sites O
in O
a O
lymphoblastoid B
cell I
line I
and O
growth-inhibitory O
effect O
of O
estrogen O
, O
anti-estrogen O
and O
bioflavonoids O
. O

Type-II O
estrogen-binding O
sites O
( O
type-II O
EBS O
) O
have O
been O
demonstrated O
in O
the O
human B
lymphoblastoid I
cell I
line I
IM-9 B
using O
a O
whole-cell O
assay O
with O
( O
6 O
, O
7-3H O
) O
estradiol O
( O
3H-E2 O
) O
as O
tracer O
. O

Our O
results O
suggest O
that O
high O
estrogen O
and O
anti-estrogen O
concentrations O
and O
flavonoids O
may O
regulate O
IM-9 B
cell O
growth O
through O
a O
common O
mechanism O
involving O
a O
binding O
interaction O
with O
type-II O
EBS O
. O

Cortivazol O
( O
CVZ O
) O
is O
a O
unique O
, O
high O
potency O
synthetic O
glucocorticoid O
, O
which O
has O
a O
phenylpyrazol O
fused O
to O
the O
A-ring O
of O
the O
steroid O
nucleus O
and O
displays O
binding O
consistent O
with O
two O
or O
more O
sites O
in O
the O
cytosol O
from O
CEM B
C7 I
cells I
( O
a O
human B
acute I
lymphoblastic I
T-cell I
line I
) O
. O

In O
mutant O
leukemic O
cells O
resistant O
to O
the O
lytic O
effects O
of O
dexamethasone O
, O
CVZ O
both O
lyses O
the O
cells O
and O
recognizes O
a O
single O
class O
of O
sites O
similar O
to O
the O
high O
affinity O
site O
in O
CEM B
C7 I
cells I
. O

We O
now O
show O
that O
: O
1 O
) O
CVZ O
has O
more O
than O
one O
binding O
site O
in O
a O
second O
, O
independent O
, O
B-cell B
line I
, O
IM-9 B
; O
2 O
) O
the O
antiglucocorticoid O
RU O
38486 O
is O
able O
to O
block O
both O
CVZ O
's O
higher O
and O
lower O
affinity O
sites O
; O
3 O
) O
all O
of O
CVZ O
's O
binding O
sites O
are O
on O
a O
protein O
immunologically O
indistinguishable O
from O
the O
human O
GR O
; O
and O
4 O
) O
freshly O
isolated O
clones O
of O
CVZ-resistant O
cells O
have O
lost O
all O
binding O
sites O
for O
CVZ O
. O

A O
similar O
infection O
with O
a O
recombinant O
retrovirus O
containing O
the O
beta-galactosidase O
gene O
with O
an O
adenovirus O
E2 O
promoter O
, O
results O
in O
beta-galactosidase O
activity O
in O
a O
limited O
number O
of O
cultured B
and O
primary O
cells O
. O

Effects O
of O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
on O
the O
human B
chronic I
myelogenous I
leukemia I
cell I
line I
RWLeu-4 B
. O

The O
effects O
of O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
( O
VD3 O
) O
on O
proliferation O
, O
differentiation O
, O
and O
macromolecular O
synthesis O
in O
the O
new O
Philadelphia B
chromosome-positive I
chronic I
myelogenous I
leukemia I
cell I
line I
, O
RWLeu-4 B
, O
were O
investigated O
. O

Treatment O
of O
RWLeu-4 B
cells I
with O
VD3 O
induced O
24R-hydroxylase O
activity O
, O
a O
marker O
of O
vitamin O
D3 O
responsiveness O
in O
many O
tissues O
. O

Exposure O
of O
RWLeu-4 B
cells I
to O
VD3 O
also O
inhibited O
proliferation O
and O
DNA O
synthesis O
with O
a O
50 O
% O
effective O
dose O
of O
3.5-10 O
nM O
within O
72 O
h O
; O
in O
addition O
, O
protein O
and O
RNA O
synthesis O
were O
inhibited O
by O
VD3 O
treatment O
. O

Exposure O
of O
RWLeu-4 B
cells I
to O
5 O
nM O
VD3 O
for O
72 O
h O
caused O
50 O
% O
of O
the O
cells O
to O
differentiate O
into O
macrophage/monocyte O
type O
cells O
as O
judged O
by O
nitroblue O
tetrazolium O
staining O
and O
adherence O
to O
plastic O
. O

Progressive O
expression O
of O
cell O
surface O
maturation-specific O
antigens O
of O
the O
monocyte/macrophage O
lineage O
was O
induced O
by O
treatment O
of O
RWLeu-4 B
cells I
with O
VD3 O
for O
24 O
to O
72 O
h O
at O
doses O
that O
inhibited O
cellular O
proliferation O
. O

c-myc O
RNA O
, O
which O
is O
constitutively O
expressed O
in O
RWLeu-4 B
cells I
, O
increased O
after O
0.5 O
h O
of O
treatment O
with O
50 O
nM O
VD3 O
and O
then O
rapidly O
decreased O
to O
barely O
detectable O
levels O
after O
4 O
h O
of O
treatment O
. O

Several O
mutants O
derived O
from O
transformed B
human I
B I
cell I
lines I
are O
defective O
in O
expressing O
major O
histocompatibility O
complex O
( O
MHC O
) O
class O
II O
genes O
. O

The O
failure O
to O
express O
a O
class O
II O
gene O
in O
at O
least O
one O
such O
mutant B
line I
has O
been O
mapped O
to O
the O
MHC O
class O
II O
X O
box O
, O
a O
conserved O
transcriptional O
element O
in O
the O
promoter O
region O
. O

Expression O
of O
a O
highly O
specific O
protein O
inhibitor O
for O
cyclic O
AMP-dependent O
protein O
kinases O
in O
interleukin-1 B
( I
IL-1 I
) I
-responsive I
cells I
blocked O
IL-1-induced O
gene O
transcription O
that O
was O
driven O
by O
the O
kappa O
immunoglobulin O
enhancer O
or O
the O
human O
immunodeficiency O
virus O
long O
terminal O
repeat O
. O

We O
show O
here O
that O
domain O
B O
is O
an O
R-responsive O
element O
in O
HeLa B
cells I
and O
is O
therefore O
not O
an O
EB1-responsive O
B-cell-specific O
element O
. O

Lymphocyte B
cell I
lines I
from O
vitamin O
D-dependent O
rickets O
type O
II O
show O
functional O
defects O
in O
the O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
receptor O
. O

Lymphocyte B
cell I
lines I
were O
established O
from O
five O
patients O
with O
vitamin O
D-dependent O
rickets O
, O
type O
II O
( O
VDDR-II O
) O
. O

Binding O
of O
[ O
3H O
] O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
( O
OH O
) O
2D3 O
) O
to O
its O
receptor O
in O
these O
cell O
lines O
was O
compared O
to O
binding O
studies O
using O
a O
T-lymphocyte B
cell I
line I
( O
S-LB1 B
) O
from O
a O
normal O
individual O
. O

The O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor O
of O
S-LB1 B
was O
comparable O
to O
the O
well-characterized O
chick O
intestinal O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor O
in O
terms O
of O
its O
ligand O
binding O
affinity O
and O
capacity O
, O
its O
mobility O
on O
5-20 O
% O
sucrose O
gradients O
, O
and O
its O
adsorption O
to O
and O
elution O
properties O
from O
DNA-cellulose O
. O

Three O
cell B
lines I
established O
from O
patients O
with O
VDDR-II O
( O
Rh- O
VDR O
, O
Sh- O
VDR O
, O
and O
Ab- O
VDR O
) O
showed O
no O
specific O
binding O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
to O
a O
receptor O
and O
treatment O
of O
the O
cultured B
cells I
with O
1 O
, O
25 O
( O
OH O
) O
2D3 O
did O
not O
stimulate O
production O
of O
24 O
, O
25-dihydroxy-vitamin O
D3 O
( O
24 O
, O
25 O
( O
OH O
) O
2D3 O
) O
, O
a O
response O
which O
is O
diagnostic O
of O
the O
presence O
of O
a O
functional O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor O
. O

In O
a O
fourth O
cell B
line I
, O
A1-VDR B
, O
the O
receptor O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
had O
a O
low O
binding O
capacity O
and O
25 O
( O
OH O
) O
D3-24-hydroxylase O
activity O
was O
not O
detectable O
. O

Induction O
of O
24 O
, O
25- O
( O
OH O
) O
2D3 O
synthesis O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
observed O
in O
the O
fifth O
cell B
line I
, O
designated O
Ro-VDR B
, O
although O
the O
sensitivity O
to O
hormone O
treatment O
was O
lower O
than O
in O
the O
control B
cell I
line I
from O
a O
normal O
donor O
. O

The O
capacity O
of O
the O
receptor O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
low O
in O
Ro-VDR B
. O

In O
all O
cell B
lines I
where O
1 O
, O
25 O
( O
OH O
) O
2D3 O
binding O
to O
a O
receptor O
was O
detectable O
, O
the O
receptor O
had O
the O
typical O
sedimentation O
coefficient O
of O
3.7 O
S O
on O
sucrose O
density O
gradient O
analysis O
. O

Binding O
and O
elution O
properties O
to O
DNA-cellulose O
, O
however O
, O
differed O
from O
normal O
in O
both O
Ro-VDR B
and O
A1-VDR B
cells I
where O
elution O
from O
DNA-cellulose O
occurred O
at O
a O
lower O
salt O
concentration O
than O
is O
typical O
of O
the O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor O
. O

While O
Ro-VDR B
cells I
showed O
typical O
nuclear O
localization O
of O
the O
unoccupied O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor O
, O
neither O
the O
unoccupied O
nor O
the O
occupied O
receptor O
from O
A1-VDR B
cells I
was O
completely O
localized O
in O
the O
nucleus O
. O

Use O
of O
these O
cell B
lines I
will O
facilitate O
further O
study O
of O
the O
molecular O
defect O
( O
s O
) O
in O
the O
receptor O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
vitamin O
D-dependent O
rickets O
type O
II O
and O
will O
allow O
a O
correlation O
with O
impairment O
of O
cellular O
functions O
. O

Transcriptional O
and O
post-transcriptional O
regulation O
of O
c-jun O
expression O
during O
monocytic O
differentiation O
of O
human B
myeloid I
leukemic I
cells I
. O

We O
studied O
the O
effects O
of O
TPA O
on O
the O
regulation O
of O
c-jun O
gene O
expression O
in O
HL-60 B
cells I
during O
monocytic O
differentiation O
. O

Low O
levels O
of O
c-jun O
transcripts O
were O
detectable O
in O
untreated B
HL-60 I
leukemic I
cells I
, O
increased O
significantly O
by O
6 O
h O
, O
and O
reached O
near O
maximal O
levels O
by O
24 O
h O
of O
exposure O
to O
32 O
nM O
TPA O
. O

Similar O
kinetics O
of O
c-jun O
induction O
by O
TPA O
were O
observed O
in O
human B
U-937 I
and O
THP-1 B
monocytic I
leukemia I
cells I
. O

TPA O
treatment O
of O
HL-60 B
cells I
in O
the O
presence O
of O
cycloheximide O
was O
associated O
with O
superinduction O
of O
c-jun O
transcripts O
. O

Run-on O
analysis O
demonstrated O
detectable O
levels O
of O
c-jun O
gene O
transcription O
in O
untreated B
HL-60 I
cells I
, O
and O
that O
exposure O
to O
TPA O
increases O
this O
rate O
3.3-fold O
. O

Treatment O
of O
HL-60 B
cells I
with O
both O
TPA O
and O
cycloheximide O
had O
no O
effect O
on O
the O
rates O
of O
c-jun O
transcription O
. O

The O
half-life O
of O
c-jun O
RNA O
as O
determined O
by O
treating O
HL-60 B
cells I
with O
TPA O
and O
actinomycin O
D O
was O
30 O
min O
. O

In O
contrast O
, O
the O
half-life O
of O
c-jun O
RNA O
in O
TPA-treated B
HL-60 I
cells I
exposed O
to O
cycloheximide O
and O
actinomycin O
D O
was O
greater O
than O
2 O
h O
. O

To O
determine O
whether O
different O
cellular O
factors O
were O
involved O
in O
E3 O
regulation O
in O
lymphocytes O
as O
compared O
with O
HeLa B
cells I
, O
both O
DNA O
binding O
and O
transfection O
analysis O
with O
the O
E3 O
promoter O
in O
both O
cell O
types O
were O
performed O
. O

Transfections O
of O
E3 O
constructs O
linked O
to O
the O
chloramphenicol O
acetyltransferase O
gene O
revealed O
that O
mutagenesis O
of O
the O
distal O
NF-kappa O
B O
motif O
( O
L2 O
) O
had O
minimal O
effects O
on O
promoter O
expression O
in O
HeLa B
cells I
, O
but O
resulted O
in O
dramatic O
decreases O
in O
expression O
by O
lymphoid O
cells O
. O

In O
contrast O
, O
mutagenesis O
of O
proximal O
NF-kappa O
B O
motif O
( O
L1 O
) O
had O
minimal O
effects O
on O
gene O
expression O
in O
both O
HeLa B
cells I
and O
lymphoid O
cells O
but O
resulted O
in O
a O
small O
, O
but O
reproducible O
, O
increase O
in O
gene O
expression O
in O
lymphoid O
cells O
when O
coupled O
to O
the O
L2 O
mutation O
. O

Stimulation O
of O
a O
human B
T-cell I
clone I
with O
anti-CD3 O
or O
tumor O
necrosis O
factor O
induces O
NF-kappa O
B O
translocation O
but O
not O
human O
immunodeficiency O
virus O
1 O
enhancer-dependent O
transcription O
. O

The O
expression O
of O
transiently O
transfected O
expression O
vectors O
under O
the O
control O
of O
the O
long O
terminal O
repeat O
( O
LTR O
) O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
or O
its O
enhancer O
sequence O
and O
the O
translocation O
of O
the O
HIV O
enhancer-binding O
protein O
NF-kappa O
B O
were O
analyzed O
in O
two O
human O
T-cell B
clones I
stimulated O
through O
their O
T-cell O
receptor O
complex O
or O
by O
tumor O
necrosis O
factor O
or O
phorbol O
12-myristate O
13-acetate O
. O

Our O
finding O
that O
induction O
of O
NF-kappa O
B O
by O
tumor O
necrosis O
factor O
or O
antibody O
to O
CD3 O
is O
not O
sufficient O
to O
induce O
HIV O
enhancer O
-dependent O
transcription O
in O
cloned B
T I
cells I
contrasts O
with O
results O
obtained O
in O
most O
lymphoblastoid B
T-cell I
lines I
and O
indicates O
that O
normal O
T O
lymphocytes O
differ O
from O
tumoral O
T O
cells O
in O
terms O
of O
requirements O
for O
HIV O
LTR O
activation O
. O

In O
order O
to O
investigate O
this O
possibility O
, O
we O
measured O
the O
concentration O
of O
VDR O
in O
PHA-activated B
peripheral I
mononuclear I
cells I
from O
10 O
XLH O
patients O
. O

Moreover O
, O
BSAP O
is O
clearly O
a O
B-cell-specific O
transcription O
factor O
, O
as O
a O
wild-type O
but O
not O
a O
mutant O
TSAP-binding O
site O
of O
the O
sea O
urchin O
functions O
only O
in O
transfected B
B I
cells I
as O
an O
upstream O
promoter O
element O
. O

These O
constructs O
were O
transfected O
into O
either O
HeLa B
cells I
, O
Jurkat B
cells I
or O
U937 B
cells I
in O
both O
the O
presence O
and O
absence O
of O
phorbol O
esters O
which O
have O
previously O
been O
demonstrated O
to O
activate O
HIV O
gene O
expression O
. O

However O
, O
viruses O
containing O
mutations O
in O
either O
the O
TAR O
loop O
sequences O
or O
stem O
secondary O
structure O
which O
were O
very O
defective O
for O
gene O
expression O
in O
untreated O
Jurkat B
cells I
, O
gave O
nearly O
wild-type O
levels O
of O
gene O
expression O
in O
phorbol B
ester-treated I
Jurkat I
cells I
but O
not O
in O
phorbol B
ester-treated I
HeLa I
or O
U937 B
cells I
. O

High O
level O
gene O
expression O
of O
these O
TAR O
mutant O
constructs O
in O
phorbol B
ester-treated I
Jurkat I
cells I
was O
eliminated O
by O
second O
site O
mutations O
in O
the O
enhancer O
region O
or O
by O
disruption O
of O
the O
tat O
gene O
. O

Southwestern O
and O
gel O
renaturation O
experiments O
with O
the O
use O
of O
purified O
protein O
fractions O
revealed O
that O
TCF-1 O
alpha O
activity O
is O
derived O
from O
a O
family O
of O
57- O
to O
53-kD O
proteins O
that O
are O
abundantly O
expressed O
in O
mature B
and I
immature I
T-cell I
lines I
( O
Jurkat B
, O
CCRF-CEM B
) O
and O
not O
in O
mature B
B I
cells I
( O
JY B
, O
Namalwa B
) O
or O
nonlymphoid B
( I
HeLa I
) I
cell I
lines I
. O

Tandem O
copies O
of O
this O
enhancer O
functioned O
synergistically O
in O
mature B
( I
Jurkat I
) I
T-cell I
lines I
as O
well O
as O
resting O
and O
activated O
immature B
( I
CCRF-CEM I
) I
T-cell I
lines I
. O

The O
TCF-1 O
alpha O
binding O
site O
was O
also O
required O
for O
TCR O
alpha O
enhancer O
activity O
in O
transcriptionally O
active O
extracts O
from O
Jurkat B
but O
not O
HeLa B
cells I
, O
confirming O
that O
TCF-1 O
alpha O
is O
a O
T-cell-specific O
transcription O
factor O
. O

This O
enhancer O
is O
inducible O
in O
K562 B
human I
erythroleukemia I
cells I
, O
increasing O
linked O
gamma-globin O
promoter O
/luciferase O
gene O
expression O
to O
170-fold O
over O
an O
enhancerless O
construct O
. O

Purified O
OTF1 O
from O
HeLa B
cells I
and O
OTF1 O
and O
OTF2 O
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy-chain O
promoter O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
, O
we O
showed O
binding O
of O
purified O
human O
NF-kappa O
B O
and O
of O
the O
NF-kappa O
B O
activated O
in O
Jurkat B
T I
cells I
to O
an O
oligonucleotide O
comprising O
the O
GM-CSF O
promoter O
element O
responsible O
for O
mediating O
responsiveness O
to O
T-cell-activating O
signals O
and O
tax1 O
. O

Unexpectedly O
, O
stimulation O
of O
cloned B
stably I
transfected I
Jurkat I
T I
cells I
leads O
to O
a O
bimodal O
pattern O
of O
beta-gal O
expression O
in O
which O
some O
cells O
express O
no O
beta-gal O
and O
others O
express O
high O
levels O
. O

Induction O
of O
Jurkat B
leukemic I
T I
cells I
with O
phorbol O
12-myristate O
13-acetate O
and O
ionomycin O
did O
not O
affect O
the O
level O
of O
FKBP O
mRNA O
. O

The O
percentage O
of O
the O
OKT8+ B
suppressor/cytotoxic I
T I
cells I
increased O
when O
the O
inflammation O
expanded O
from O
scanty O
to O
moderate O
( O
P O
less O
than O
0.02 O
) O
. O

In O
addition O
, O
a O
direct O
correlation O
exists O
between O
the O
diameter O
of O
the O
PCVs O
and O
both O
the O
percentage O
of O
the O
OKT8+ B
T I
cells I
( O
P O
less O
than O
0.04 O
) O
and O
the O
Leu-7+ O
natural O
killer O
cells O
( O
P O
less O
than O
0.03 O
) O
. O

Reactivity O
of O
lymphocytes B
to O
a O
progesterone O
receptor-specific O
monoclonal O
antibody O
. O

To O
characterize O
the O
receptor-bearing O
subset O
, O
CD8+ B
and I
CD4+ I
cells I
were O
depleted O
by O
complement-dependent O
lysis O
. O

Depletion O
of O
CD8+ B
cells I
was O
accompanied O
by O
62 O
+/- O
18 O
% O
loss O
of O
progesterone B
receptor-bearing I
cells I
, O
while O
depletion O
of O
CD4+ B
cells I
resulted O
in O
a O
twofold O
increase O
in O
the O
number O
of O
positively O
staining O
lymphocytes B
. O

In O
nonpregnancy B
lymphocytes I
a O
3-day O
PHA O
treatment O
, O
as O
well O
as O
allogeneic O
stimulation O
, O
resulted O
in O
a O
significant O
increase O
in O
the O
number O
of O
receptor-containing O
cells O
. O

These O
results O
suggest O
that O
pregnancy O
, O
but O
not O
nonpregnancy O
, O
lymphocytes B
contain O
progesterone O
binding O
structures O
, O
and O
that O
these O
are O
inducible O
by O
mitogenic O
or O
alloantigenic O
stimuli O
. O

Activation O
of O
human B
CD4 I
T I
lymphocytes I
. O

Interaction O
of O
fibronectin O
with O
VLA-5 O
receptor O
on O
CD4 B
cells I
induces O
the O
AP-1 O
transcription O
factor O
. O

Fibronectin O
synergized O
with O
anti-CD3 O
antibody O
to O
promote O
CD4 O
cell O
proliferation O
in O
a O
serum-free O
culture O
system O
whereas O
no O
proliferation O
was O
observed O
when O
CD4 B
cells I
were O
cultured O
with O
anti-CD3 O
alone O
or O
fibronectin O
alone O
. O

In O
addition O
, O
anti-CD29 O
( O
integrin O
beta O
1 O
) O
as O
well O
as O
anti-VLA-5 O
( O
human O
fibronectin O
receptor O
) O
antibodies O
blocked O
this O
CD4 B
cell I
activation O
in O
this O
system O
. O

Although O
anti-CD3 O
alone O
or O
fibronectin O
alone O
can O
not O
induce O
IL-2 O
message O
by O
CD4 B
cells I
, O
the O
combination O
of O
anti-CD3 O
plus O
fibronectin O
induced O
IL-2 O
message O
by O
CD4 B
cells I
. O

Thus O
the O
VLA-5 O
fibronectin O
receptor O
on O
CD4 B
cells I
can O
play O
a O
complementary O
role O
in O
CD3 O
- O
TCR O
-mediated O
signal O
transduction O
through O
its O
interaction O
with O
fibronectin O
. O

Consistent O
with O
findings O
obtained O
with O
transient O
expression O
assays O
, O
we O
observed O
marked O
accumulation O
of O
the O
transcription O
factor O
NF-kappa O
B O
in O
the O
nucleus O
of O
Namalwa B
B I
lymphoid I
cells I
, O
which O
constitutively O
express O
Tax O
. O

In O
contrast O
, O
NF-kappa O
B O
activity O
was O
not O
detected O
in O
the O
nucleus O
following O
long-term O
expression O
of O
Tax O
in O
Jurkat B
T I
lymphocytes I
. O

The O
ability O
of O
both O
mitogens O
and O
cytokines O
to O
activate O
NF-kappa O
B O
was O
also O
blocked O
in O
Jurkat B
cells I
constitutively O
expressing O
Tax O
. O

We O
have O
identified O
and O
separated O
four O
nuclear O
proteins O
from O
C81-66-45 O
cells O
, O
an O
HTLV-I B
immortalized I
Tax-expressing I
human I
T-lymphocyte I
line I
( O
Salahuddin O
et O
al. O
, O
1983 O
) O
, O
that O
interact O
with O
the O
TRE-DNA O
, O
none O
of O
which O
are O
identical O
with O
the O
Tax-protein O
. O

These O
proteins O
are O
differentially O
expressed O
in O
human B
glioblastoma I
and I
neuroblastoma I
cell I
lines I
. O

Treatment O
of O
an O
HTLV-I B
infected I
human I
T-cell I
line I
with O
H-7 O
blocked O
specifically O
accumulation O
of O
the O
unspliced O
gag-pol O
mRNA O
, O
resulting O
in O
the O
decreased O
Gag O
protein O
synthesis O
that O
corresponds O
with O
the O
decreased O
in O
vivo O
phosphorylation O
of O
Rex O
. O

Increased O
glucocorticoid O
responsiveness O
of O
CD4+ B
T-cell I
clonal I
lines I
grown O
in O
serum-free O
media O
. O

CEM-C7 B
, O
a O
human B
leukemic I
CD4+ I
T-lymphocyte I
cell I
line I
and O
three O
of O
its O
subclones O
, O
CEM-4R4 B
, O
CEM-3R43 B
, O
and O
ICR-27 B
, O
previously O
cultured O
in O
a O
medium O
supplemented O
with O
5 O
to O
10 O
% O
fetal O
bovine O
serum O
, O
have O
been O
adapted O
to O
serum-free O
media O
. O

While O
growing O
either O
with O
or O
without O
albumin O
, O
the O
several O
clonal B
lines I
of O
CEM B
cells O
displayed O
growth O
similar O
to O
serum-supplemented O
cultures O
. O

Cell O
proliferation O
of O
CEM-C7 B
cells O
cultured O
in O
both O
serum-free O
media O
has O
been O
sustained O
for O
3 O
mo O
. O

with O
culture O
doubling O
times O
of O
about O
25 O
h O
for O
both O
serum-supplemented B
and I
serum-free I
cultures I
( O
viability O
greater O
than O
or O
equal O
to O
90 O
% O
) O
. O

When O
grown O
in O
serum-free O
medium O
, O
CEM-C7 B
cells O
exhibited O
increased O
steroid O
responsiveness O
as O
evidenced O
by O
increased O
glucocorticoid O
receptor O
binding O
sites O
, O
increased O
induction O
of O
glutamine O
synthetase O
, O
and O
cell O
lysis O
at O
lower O
concentrations O
of O
steroid O
. O

Receptor O
mutant O
subclones O
of O
CEM-C7 B
, O
which O
are O
proven O
to O
be O
completely O
unresponsive O
to O
micromolar O
concentrations O
of O
dexamethasone O
when O
grown O
in O
serum-supplemented O
medium O
, O
become O
partially O
sensitive O
to O
the O
hormone O
after O
growth O
in O
defined O
medium O
. O

The O
increased O
sensitivity O
of O
CEM-C7 B
cells I
and O
its O
subclones O
to O
dexamethasone O
in O
serum-free O
medium O
returned O
to O
previous O
levels O
when O
these O
cells O
were O
recultured O
in O
serum-containing O
medium O
. O

We O
have O
identified O
two O
human B
pre-B-cell I
lines I
that O
contain O
extremely O
low O
levels O
of O
OTF-2 O
yet O
still O
express O
high O
levels O
of O
steady-state O
immunoglobulin O
heavy-chain O
mRNA O
in O
vivo O
and O
efficiently O
transcribe O
an O
immunoglobulin O
gene O
in O
vitro O
. O

Addition O
of O
a O
highly O
enriched O
preparation O
of O
OTF-1 O
made O
from O
one O
of O
these O
pre-B B
cells I
or O
from O
HeLa B
cells I
specifically O
stimulated O
in O
vitro O
transcription O
of O
an O
immunoglobulin O
gene O
. O

Octamer-dependent O
activation O
of O
a O
reporter O
plasmid O
or O
NF-kappa O
B O
-dependent O
activation O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
enhancer O
was O
inhibited O
when O
the O
appropriate O
phosphorothioate O
oligonucleotide O
was O
added O
to O
a O
transiently B
transfected I
B I
cell I
line I
. O

Addition O
of O
phosphorothioate O
oligonucleotides O
that O
contained O
the O
octamer O
consensus O
to O
Jurkat B
T I
leukemia I
cells I
inhibited O
interleukin-2 O
( O
IL-2 O
) O
secretion O
to O
a O
degree O
similar O
to O
that O
observed O
with O
a O
mutated O
octamer O
site O
in O
the O
IL-2 O
enhancer O
. O

( O
i O
) O
Acute O
transfection O
and O
expression O
of O
EBNA-2 O
under O
control O
of O
simian O
virus O
40 O
or O
Moloney O
murine O
leukemia O
virus O
promoters O
resulted O
in O
increased O
LMP1 O
expression O
in O
P3HR-1-infected B
Burkitt I
's I
lymphoma I
cells I
and O
the O
P3HR-1 B
or O
Daudi B
cell I
line I
. O

( O
iii O
) O
LMP1 O
expression O
in O
Daudi B
and O
P3HR-1-infected B
cells I
was O
controlled O
at O
the O
mRNA O
level O
, O
and O
EBNA-2 O
expression O
in O
Daudi B
cells I
increased O
LMP1 O
mRNA O
. O

( O
iv O
) O
No O
other O
EBV O
genes O
were O
required O
for O
EBNA-2 O
transactivation O
of O
LMP1 O
since O
cotransfection O
of O
recombinant O
EBNA-2 O
expression O
vectors O
and O
genomic O
LMP1 O
DNA O
fragments O
enhanced O
LMP1 O
expression O
in O
the O
EBV-negative B
B-lymphoma I
cell I
lines I
BJAB B
, O
Louckes B
, O
and O
BL30 B
. O

Heat O
shock O
caused O
an O
increase O
in O
c-fos O
and O
c-jun O
mRNA O
levels O
and O
a O
decrease O
in O
c-myc O
mRNA O
levels O
in O
pre-B B
( I
Hyon I
) I
and I
T I
( I
DND-41 I
) I
cell I
lines I
as O
well O
as O
in O
freshly O
isolated O
normal O
human O
thymocytes O
. O

The O
changes O
in O
the O
mRNA O
levels O
of O
these O
protooncogenes O
in O
Hyon B
cells I
were O
most O
pronounced O
at O
42 O
and O
43 O
degrees O
C O
; O
kinetic O
analysis O
demonstrated O
that O
the O
changes O
could O
be O
detected O
within O
30 O
min O
of O
heat O
shock O
. O

Secondarily O
, O
heat O
shock O
of O
Hyon B
cells I
stabilized O
the O
c-myc O
mRNA O
level O
by O
increasing O
its O
half-life O
from O
24 O
to O
45 O
min O
. O

Using O
a O
monoclonal O
antibody O
, O
Lt-4 O
, O
directed O
against O
human O
T O
cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
trans-activator O
( O
tax1 O
) O
antigen O
, O
we O
examined O
the O
expression O
of O
tax1 O
and O
related O
antigens O
in O
a O
variety O
of O
T B
cell I
lines I
bearing O
HTLV-I O
and O
related O
retroviruses O
, O
simian O
T O
cell O
leukemia O
virus O
type O
I O
( O
STLV-I O
) O
and O
HTLV-II O
, O
by O
immunofluorescence O
and O
immunoblot O
assays O
. O

Lt-4 O
reacted O
with O
all O
HTLV-I-bearing B
cell I
lines I
tested O
and O
five O
out O
of O
eight O
simian B
cell I
lines I
bearing O
STLV-I O
, O
but O
not O
with O
an O
HTLV-II-bearing B
cell I
line I
. O

Lt-4 O
detected O
40 O
kd O
tax1 O
antigen O
molecules O
in O
most O
HTLV-I-bearing B
cell I
lines I
except O
one O
cell O
line O
that O
expressed O
39 O
kd O
tax1 O
antigen O
. O

In O
the O
STLV-I-bearing B
T I
cell I
lines I
, O
tax1-related O
antigen O
molecules O
detected O
by O
Lt-4 O
were O
heterogeneous O
, O
having O
molecular O
weights O
in O
the O
range O
of O
36-41 O
kd O
. O

Characterization O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
enhancer-binding O
proteins O
from O
the O
human B
T-cell I
line I
Jurkat B
. O

We O
show O
that O
at O
least O
one O
inducible O
, O
C1 O
, O
and O
one O
constitutive O
, O
C2 O
, O
protein O
can O
bind O
to O
the O
HIV O
enhancer O
in O
Jurkat B
cells I
. O

Whereas O
c-Fos/c-Jun O
heterodimers O
do O
not O
exist O
in O
B B
cells I
, O
they O
form O
and O
bind O
to O
the O
X2-box O
in O
class B
II I
nonexpressing I
cells I
. O

The O
effects O
of O
a O
competitive O
progesterone O
antagonist O
( O
RU486 O
) O
and O
a O
specific O
glucocorticoid O
receptor O
blocker O
( O
RU43044 O
) O
were O
tested O
on O
the O
release O
of O
a O
blocking O
factor O
by O
progesterone-treated B
pregnancy I
lymphocytes I
. O

In O
this O
work O
we O
show O
that O
the O
monoclonal O
antibody O
KN O
382/EC1 O
raised O
against O
the O
rabbit O
59-kDa O
protein O
reacts O
with O
9S O
, O
untransformed O
glucocorticoid O
receptor O
complexes O
in O
cytosol O
prepared O
from O
human B
IM-9 I
lymphocytes I
but O
not O
with O
4S O
salt-transformed O
receptors O
. O

When O
p56 O
is O
immunoadsorbed O
from O
IM-9 B
cell I
cytosol O
, O
both O
the O
70- O
and O
90-kDa O
heat O
shock O
proteins O
are O
coadsorbed O
in O
an O
immune-specific O
manner O
. O

The O
effect O
of O
1 O
, O
25-dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
( O
OH O
) O
2 O
) O
D3 O
] O
, O
a O
steroid O
hormone O
with O
immunomodulating O
properties O
, O
on O
nuclear O
factor O
kappa O
B O
( O
NF-kappa O
B O
) O
proteins O
was O
examined O
in O
in B
vitro I
activated I
normal I
human I
lymphocytes I
by O
Western O
blot O
analysis O
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF-kappa O
B O
in O
Jurkat B
cells I
transiently O
transfected O
with O
a O
construct O
containing O
four O
tandem O
repeats O
of O
the O
NF-kappa O
B O
binding O
sequence O
of O
the O
immunoglobulin O
kappa O
light O
chain O
gene O
linked O
to O
the O
chloramphenicol O
acetyltransferase O
reporter O
gene O
. O

The O
expression O
vector O
was O
cotransfected O
with O
the O
chloramphenicol O
acetyl O
transferase O
( O
CAT O
) O
reporter O
gene O
regulated O
by O
the O
thymidine O
kinase O
promoter O
containing O
GAL4 O
DNA O
binding O
sites O
into O
NIH B
3T3 I
, O
293 B
, O
K562 B
, O
and O
Jurkat B
cell I
lines I
. O

MZF-1 O
represses O
CAT O
reporter O
gene O
expression O
via O
GAL4 O
binding O
sites O
in O
the O
nonhematopoietic B
cell I
lines I
NIH B
3T3 I
and O
293 B
. O

In O
contrast O
, O
MZF-1 O
activates O
CAT O
reporter O
gene O
expression O
in O
the O
hematopoietic B
cell I
lines I
K562 B
and O
Jurkat B
. O

MZF-1 O
transcriptional O
regulation O
of O
this O
physiologically O
relevant O
promoter O
was O
assessed O
in O
both O
hematopoietic B
and O
nonhematopoietic B
cell I
lines I
. O

MZF-1 O
expression O
vectors O
were O
cotransfected O
with O
the O
luciferase O
reporter O
plasmids O
regulated O
by O
the O
CD34 O
promoter O
into O
both O
nonhematopoietic B
and I
hematopoietic I
cell I
lines I
. O

As O
with O
the O
heterologous O
DNA O
binding O
domain O
, O
MZF-1 O
represses O
reporter O
gene O
expression O
in O
nonhematopoietic B
cell I
lines I
and O
activates O
expression O
in O
hematopoietic B
cell I
lines I
. O

Activation O
of O
CD34 O
expression O
in O
hematopoietic B
cell I
lines I
is O
dependent O
on O
the O
presence O
of O
intact O
MZF-1 O
binding O
sites O
. O

The O
DNA-binding O
properties O
of O
two O
heat O
shock O
factors O
, O
HSF1 O
and O
HSF3 O
, O
are O
induced O
in O
the O
avian B
erythroblast I
cell I
line I
HD6 B
. O

HSF3 O
is O
constitutively O
expressed O
in O
the O
erythroblast B
cell I
line I
HD6 I
, O
the O
lymphoblast B
cell I
line I
MSB I
, O
and O
embryo B
fibroblasts I
, O
and O
yet O
its O
DNA-binding O
activity O
is O
induced O
only O
upon O
exposure O
of O
HD6 O
cells O
to O
heat O
shock O
. O

Acquisition O
of O
HSF3 O
DNA-binding O
activity O
in O
HD6 B
cells I
is O
accompanied O
by O
oligomerization O
from O
a O
non-DNA-binding O
dimer O
to O
a O
DNA-binding O
trimer O
, O
whereas O
the O
effect O
of O
heat O
shock O
on O
HSF1 O
is O
oligomerization O
of O
an O
inert O
monomer O
to O
a O
DNA-binding O
trimer O
. O

Direct O
demonstration O
of O
NFATp O
dephosphorylation O
and O
nuclear O
localization O
in O
activated B
HT-2 I
cells I
using O
a O
specific O
NFATp O
polyclonal O
antibody O
. O

Treatment O
of O
immunoprecipitated O
NFATp O
from O
untreated O
HT-2 B
cells I
with O
calcineurin O
resulted O
in O
the O
dephosphorylation O
of O
NFATp O
, O
demonstrating O
that O
NFATp O
is O
an O
in O
vitro O
substrate O
for O
calcineurin O
. O

NFATp O
immunoprecipitated O
from O
32P-labeled B
HT-2 I
cells I
migrated O
as O
an O
approximately O
120-kDa O
protein O
that O
was O
localized O
to O
the O
cytosol O
of O
the O
cells O
. O

However O
, O
supershift O
assays O
using O
the O
available O
mAb O
recognizing O
the O
T O
cell O
NFATc O
revealed O
no O
detectable O
NFATc O
protein O
in O
nuclear O
and O
cytoplasmic O
extracts O
from O
CD16- O
or O
phorbol B
ester-stimulated I
cells I
at O
any O
time O
tested O
, O
up O
to O
4 O
h O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural B
killer I
cell I
line I
( O
NKL B
) O
to O
IL-2 O
leads O
to O
the O
phosphorylation O
of O
Stat1 O
alpha O
, O
Stat1 O
beta O
, O
and O
Stat3 O
, O
as O
well O
as O
of O
two O
Stat-related O
proteins O
, O
p94 O
and O
p95 O
. O

Here O
, O
we O
show O
that O
SE O
induce O
dynamic O
changes O
in O
the O
expression O
of O
and O
signal O
transduction O
through O
the O
IL-2 O
receptor O
( O
IL-2R O
) O
beta O
and O
gamma O
chains O
( O
IL-2R O
beta O
and O
IL-2R O
gamma O
) O
in O
human B
antigen-specific I
CD4+ I
T-cell I
lines I
. O

In O
conclusion O
, O
our O
data O
suggest O
that O
SE O
can O
modulate O
IL-2R O
expression O
and O
signal O
transduction O
involving O
the O
Jak/Stat O
pathway O
in O
CD4+ B
T-cell I
lines I
. O

In O
contrast O
to O
hematopoietic O
cells O
, O
I B
kappa I
B I
alpha-/- I
embryonic I
fibroblasts I
show O
minimal O
constitutive O
NF-kappa O
B O
, O
as O
well O
as O
normal O
signal-dependent O
NF-kappa O
B O
activation O
that O
is O
concomitant O
with O
I O
kappa O
B O
beta O
degradation O
. O

Analysis O
of O
the O
expression O
of O
human O
I O
kappa O
B O
alpha O
protein O
in O
stable O
transfectants O
of O
mouse B
70Z/3 I
cells I
shows O
that O
, O
as O
for O
the O
endogenous O
murine O
protein O
, O
exogenous O
I O
kappa O
B O
alpha O
is O
degraded O
in O
response O
to O
inducers O
of O
NF-kappa O
B O
activity O
, O
such O
as O
phorbol O
myristate O
acetate O
or O
lipopolysaccharide O
. O

By O
expressing O
mutant O
forms O
of O
the O
human O
protein O
in O
this O
cell B
line I
, O
we O
have O
been O
able O
to O
delineate O
the O
sequences O
responsible O
for O
both O
the O
ligand-induced O
phosphorylation O
and O
the O
degradation O
of O
I O
kappa O
B O
alpha O
. O

An O
IRF-1 O
-dependent O
pathway O
of O
DNA O
damage-induced O
apoptosis O
in O
mitogen-activated B
T I
lymphocytes I
. O

Lymphocytes B
are O
particularly O
susceptible O
to O
DNA O
damage-induced O
apoptosis O
, O
a O
response O
which O
may O
serve O
as O
a O
form O
of O
'altruistic O
suicide O
' O
to O
counter O
their O
intrinsic O
high O
potential O
for O
mutation O
and O
clonal O
expansion O
. O

The O
tumour O
suppressor O
p53 O
has O
been O
shown O
to O
regulate O
this O
type O
of O
apoptosis O
in O
thymocytes O
, O
but O
an O
as O
yet O
unknown O
, O
p53 O
-independent O
pathway O
( O
s O
) O
appears O
to O
mediate O
the O
same O
event O
in O
mitogen-activated B
mature I
T I
lymphocytes I
. O

B-lymphoblastoid B
cell I
lines I
from O
multiple O
sclerosis O
patients O
and O
a O
healthy O
control O
producing O
a O
putative O
new O
human O
retrovirus O
and O
Epstein-Barr O
virus O
. O

On O
several O
occasions O
we O
have O
observed O
retrovirus-like O
particles O
( O
RVLPs O
) O
by O
transmission O
electron O
microscopy O
( O
EM O
) O
of O
cultured B
T I
cells I
from O
a O
patient O
with O
MS O
. O

Later O
we O
established O
spontaneously O
formed O
B-lymphoblastoid B
cell I
lines I
( O
LCLs B
) O
from O
a O
patient O
with O
an O
MS-like O
disease O
and O
from O
another O
patient O
with O
MS O
who O
had O
a O
reactivated O
Epstein-Barr O
virus O
( O
EBV O
) O
infection O
. O

Both O
LCLs B
were O
found O
by O
EM O
to O
produce O
RVLP O
and O
EBV O
particles O
. O

Reverse O
transcriptase O
( O
RT O
) O
assays O
were O
positive O
in O
purified O
viral O
material O
from O
both O
LCLs B
. O

To O
substantiate O
these O
findings O
we O
initiated O
an O
intensified O
culturing O
procedure O
and O
were O
able O
to O
establish O
LCLs B
from O
5 O
out O
of O
21 O
consecutive O
MS O
patients O
and O
1 O
out O
of O
13 O
consecutive O
healthy O
controls O
. O

All O
LCLs B
were O
found O
to O
produce O
both O
RVLP O
and O
EBV O
particles O
by O
EM O
. O

Northern O
hybridization O
data O
showed O
that O
B4-2 O
is O
not O
a O
lymphoid O
specific O
gene O
and O
is O
expressed O
in O
a O
hepatoma B
cell I
line I
and O
also O
weakly O
transcribed O
or O
absent O
in O
a O
variety O
of O
other O
cells O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL-2 O
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 O
and O
JAK3 O
, O
but O
demonstrated O
that O
IL-2 O
stimulated O
JAK3 O
to O
a O
significantly O
larger O
extent O
than O
JAK1 O
in O
human O
T O
lymphocytes O
and O
the O
YT B
cell I
line I
. O

Furthermore O
, O
when O
human O
IL-2R O
beta O
was O
stably O
expressed O
in O
murine B
BA/F3 I
cells I
, O
robust O
IL-2 O
-induced O
proliferation O
and O
JAK3 O
activation O
occurred O
without O
detectable O
involvement O
of O
either O
JAK1 O
, O
JAK2 O
or O
TYK2 O
. O

DHEA O
binding O
sites O
were O
examined O
using O
a O
whole-cell O
binding O
assay O
in O
a O
human B
T I
lymphoid I
cell I
line I
, O
PEER B
, O
revealing O
that O
a O
single O
class O
of O
high-affinity O
binding O
sites O
for O
DHEA O
( O
dissociation O
constant O
= O
7.4 O
+/- O
0.53 O
nmol/L O
, O
mean O
+/- O
SE O
, O
n O
= O
4 O
) O
was O
greatly O
increased O
when O
treated O
with O
DHEA O
, O
phorbol-12-myristate-13-acetate O
, O
and O
the O
Ca2+ O
ionophore O
A23187 O
. O

Constitutive O
expression O
of O
HIV-1 O
tat O
protein O
in O
human B
Jurkat I
T I
cells I
using O
a O
BK O
virus O
vector O
. O

The O
production O
and O
characterization O
of O
Jurkat B
cell I
lines I
that O
constitutively O
express O
functional O
human O
immune O
deficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
tat O
protein O
, O
using O
a O
BK O
virus O
plasmid O
expression O
vector O
and O
HIV-1 O
tat O
cDNA O
, O
is O
described O
. O

An O
increased O
growth O
rate O
of O
these O
Jurkat-tat B
cell I
lines I
as O
compared O
with O
control B
cell I
lines I
was O
observed O
. O

An O
Epstein-Barr B
virus I
( I
EBV I
) I
-transformed I
cell I
line I
derived O
from O
her O
lymphocytes O
had O
normal O
gamma O
c O
expression O
but O
lacked O
Jak3 O
protein O
and O
had O
greatly O
diminished O
Jak3 O
messenger O
RNA O
. O

The O
lack O
of O
Jak3 O
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL-4 O
to O
activate O
Stat6 O
in O
the O
EBV-transformed B
cell I
line I
from O
the O
patient. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma O
c O
are O
dependent O
on O
Jak3 O
and O
that O
Jak3 O
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

Flow O
cytometry O
showed O
that O
L-selectin O
was O
expressed O
on O
fresh O
ATL B
cells I
along O
with O
other O
activation O
antigens O
. O

Northern O
blot O
analysis O
showed O
that O
ATL B
cells I
overexpressed O
that O
L-selectin O
mRNA O
and O
that O
the O
level O
was O
aberrantly O
upregulated O
after O
PMA O
stimulation O
. O

Intravenous O
injection O
of O
a O
rat B
T-cell I
line I
that O
overexpresses O
L-selectin O
showed O
increased O
organ O
infiltration O
. O

The O
induction O
of O
Tax O
expression O
in O
JPX9 B
cells I
resulted O
in O
about O
a O
twofold O
increase O
in O
the O
mRNA O
expression O
levels O
compared O
with O
the O
basal O
level O
. O

These O
results O
indicated O
that O
ATL B
cells I
constitutively O
overexpress O
the O
L-selectin O
gene O
that O
can O
be O
transactivated O
by O
HTLV-1 O
Tax O
. O

The O
overexpression O
of O
L-selectin O
, O
as O
well O
as O
of O
inflammatory O
cytokines O
, O
by O
ATL B
cells I
may O
provide O
a O
basis O
for O
ATL B
cells I
to O
attach O
the O
vascular O
endothelium O
, O
leading O
to O
transmigration O
and O
organ O
infitration O
. O

Human O
herpesvirus O
6 O
variant O
A O
, O
but O
not O
variant O
B O
, O
infects O
EBV-positive B
B I
lymphoid I
cells I
, O
activating O
the O
latent O
EBV O
genome O
through O
a O
BZLF-1 O
-dependent O
mechanism O
. O

Human O
herpesvirus O
6 O
, O
a O
predominantly O
T O
lymphotropic O
virus O
, O
has O
been O
recently O
shown O
to O
infect O
some O
EBV-positive B
B I
cell I
lines I
, O
and O
to O
induce O
in O
them O
the O
activation O
of O
the O
EBV O
lytic O
cycle O
. O

Here O
we O
have O
confirmed O
and O
extended O
such O
observations O
, O
showing O
that O
( O
1 O
) O
this O
phenomenon O
is O
restricted O
to O
the O
variant O
A O
of O
HHV-6 O
: O
in O
fact O
two O
isolates O
belonging O
to O
the O
HHV-6 O
variant O
B O
( O
BA92 O
and O
Z29 O
) O
were O
neither O
able O
to O
infect O
any O
B B
cell I
line I
, O
independently O
of O
the O
EBV O
status O
, O
nor O
to O
induce O
the O
EBV O
genome O
expression O
. O

The O
only O
exception O
is O
represented O
by O
the O
P3HR1 B
cells I
, O
in O
which O
, O
however O
, O
the O
infection O
by O
the O
variant O
B O
does O
not O
determine O
induction O
of O
EBV O
antigens O
; O
( O
2 O
) O
the O
presence O
of O
the O
EBV O
genome O
contributes O
to O
the O
susceptibility O
of O
the O
B B
cell I
lines I
to O
HHV-6 O
infection O
, O
increasing O
the O
binding O
sites O
and O
the O
percentage O
of O
infectable O
cells O
, O
as O
detected O
by O
immunoelectron O
microscopy O
; O
and O
( O
3 O
) O
HHV-6 B
infected I
T I
cells I
, O
transfected O
with O
plasmids O
bearing O
the O
promoter O
regions O
of O
the O
EBV O
early O
genes O
BZLF1 O
and O
BMRF1 O
, O
show O
a O
strong O
transactivation O
of O
these O
promoters O
. O

Transient O
expression O
of O
CD69 O
promoter-based O
reporter O
gene O
constructs O
in O
K562 B
cells I
indicated O
that O
the O
proximal O
promoter O
region O
spanning O
positions O
-78 O
to O
+16 O
contained O
the O
cis-acting O
sequences O
necessary O
for O
basal O
and O
phorbol O
12-myristate O
13-acetate-inducible O
transcription O
of O
the O
CD69 O
gene O
. O

Promoter O
function O
of O
the O
5 O
' O
flanking O
region O
of O
the O
thromboxane O
receptor O
gene O
was O
evaluated O
by O
transfection O
of O
thromboxane O
receptor O
gene O
promoter/chloramphenicol O
acetyltransferase O
( O
CAT O
) O
chimera O
plasmids O
into O
platelet-like O
K562 B
cells I
. O

Functional O
analysis O
of O
5 O
' O
deletion O
constructs O
in O
transfected O
K562 B
cells I
and O
gel O
mobility O
shift O
localized O
the O
major O
phorbol O
ester-responsive O
motifs O
in O
the O
thromboxane O
receptor O
gene O
promoter O
to O
a O
cluster O
of O
activator O
protein-2 O
( O
AP-2 O
) O
binding O
consensus O
sites O
located O
approximately O
1.8 O
kb O
5 O
' O
from O
the O
transcription O
initiation O
site O
. O

To O
identify O
transcription O
factors O
binding O
to O
PRE-I O
, O
we O
screened O
a O
cDNA O
expression O
library O
from O
Jurkat B
T I
cells I
and O
isolated O
a O
cDNA O
encoding O
nuclear O
factor O
( O
NF O
) O
-IL6 O
( O
also O
known O
as O
C/EBP O
beta O
) O
. O

NF-IL6 O
mRNA O
was O
found O
in O
human B
Jurkat I
T I
cells I
and O
in O
the O
mouse B
Th2 I
clone I
D10 B
, O
but O
not O
in O
Th1 B
clone I
29 I
. O

PRE-I O
forms O
multiple O
DNA-protein O
complexes O
with O
nuclear O
extracts O
from O
Jurkat B
cells I
. O

Overexpression O
of O
NF-IL6 O
enhanced O
expression O
of O
the O
chloramphenicol O
acetyl O
transferase O
reporter O
gene O
linked O
to O
the O
PRE-I-thymidine O
kinase O
or O
the O
human O
IL-4 O
promoter O
more O
than O
10-fold O
in O
Jurkat B
cells I
. O

Identification O
of O
an O
I O
kappa O
B O
alpha-associated O
protein O
kinase O
in O
a O
human B
monocytic I
cell I
line I
and O
determination O
of O
its O
phosphorylation O
sites O
on O
I O
kappa O
B O
alpha O
. O

In O
this O
study O
, O
we O
have O
identified O
a O
kinase O
in O
cell O
extracts O
from O
the O
LPS-stimulated B
human I
monocytic I
cell I
line I
, O
THP-1 B
, O
that O
specifically O
binds O
and O
phosphorylates O
I O
kappa O
B O
alpha O
. O

LPS O
stimulation O
transiently O
enhanced O
the O
I O
kappa O
B O
alpha O
-bound O
kinase O
activity O
in O
THP-1 B
cells I
. O

Moreover O
, O
we O
show O
that O
the O
peptide O
, O
corresponding O
to O
the O
C-terminal O
acidic O
domain O
of O
I O
kappa O
B O
alpha O
, O
blocked O
the O
LPS-induced O
NF-kappa O
B O
activation O
as O
well O
as O
inducible O
phosphorylation O
of O
endogenous O
I O
kappa O
B O
alpha O
in O
a O
cell-free O
system O
using O
THP-1 B
cells I
. O

The O
human O
TCF-1 O
gene O
encodes O
a O
nuclear O
DNA-binding O
protein O
uniquely O
expressed O
in O
normal B
and I
neoplastic I
T-lineage I
lymphocytes I
. O

TCF-1 O
mRNA O
was O
originally O
found O
to O
be O
expressed O
in O
a O
T O
cell-specific O
fashion O
within O
a O
set O
of O
human B
and I
mouse I
cell I
lines I
. O

As O
expected O
, O
the O
TCF-1 O
protein O
was O
detectable O
only O
in O
cell B
lines I
of I
T I
lineage I
. O

Immunohistochemistry O
on O
a O
panel O
of O
human O
tissues O
revealed O
that O
the O
TCF-1 O
protein O
was O
found O
exclusively O
in O
thymocytes O
and O
in O
CD3+ B
T I
cells I
in O
peripheral O
lymphoid O
tissues O
. O

Here O
we O
report O
that O
cross-linking O
of O
Fc O
gamma O
RI O
or O
Fc O
gamma O
RII O
by O
adherent O
human O
IgG O
or O
by O
specific O
anti-Fc O
gamma O
R O
mAb O
activates O
HIV-1 O
gene O
expression O
in O
the O
human B
monocytic I
cell I
line I
BF24 B
and O
increased O
HIV O
RNA O
expression O
in O
monocytes O
from O
HIV O
infected O
patients O
as O
assayed O
by O
reverse O
transcription-PCR O
. O

In O
THP-1 B
cells I
, O
Fc O
gamma O
R O
cross-linking O
induced O
NF-kappa O
B O
, O
which O
is O
known O
to O
bind O
to O
the O
regulatory O
region O
of O
the O
long O
terminal O
repeat O
( O
LTR O
) O
of O
HIV-1 O
and O
to O
activate O
HIV-1 O
transcription O
. O
Anti-TNF-alpha O
antibody O
but O
not O
anti-IL-1 O
beta O
antibody O
strongly O
inhibited O
both O
the O
induction O
of O
HIV-1- O
LTR O
-driven O
transcription O
and O
the O
induction O
of O
NF-kappa O
B O
by O
Fc O
gamma O
R O
cross-linking O
. O

Signalling O
via O
CD28 O
of O
human B
naive I
neonatal I
T I
lymphocytes I
. O

We O
found O
that O
the O
TCL1 O
gene O
was O
overexpressed O
in O
the O
PBLs O
of O
an O
AT O
patient O
with O
a O
large B
clonal I
T-cell I
population I
exhibiting O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
but O
not O
in O
the O
lymphocytes O
of O
the O
other O
cases O
. O

These O
data O
indicate O
that O
TCL1 O
is O
activated O
in O
preleukemic B
clonal I
cells I
as O
a O
consequence O
of O
chromosome O
translocation O
involving O
sequences O
from O
the O
TCR O
locus O
at O
14q11 O
. O

Inhibition O
of O
endogenous O
C/EBP O
proteins O
, O
using O
either O
an O
excess O
of O
C/EBP O
binding O
sites O
or O
a O
trans- O
dominant O
negative O
inhibitor O
, O
demonstrated O
that O
C/EBP O
proteins O
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV-1 O
LTR O
transcription O
in O
the O
promonocytic B
cell I
line I
U937 I
. O

Northern O
( O
RNA O
) O
blots O
and O
binding O
assays O
showed O
that O
NF-IL6 O
is O
the O
only O
known O
C/EBP O
family O
member O
which O
is O
increased O
when O
U937 B
cells I
are O
activated O
. O

However O
, O
transcription O
from O
crippled O
HIV-1 O
LTRs O
lacking O
C/EBP O
sites O
can O
still O
be O
induced O
following O
activation O
of O
U937 B
cells I
. O

NF-M O
( O
chicken O
C/EBP O
beta O
) O
induces O
eosinophilic O
differentiation O
and O
apoptosis O
in O
a O
hematopoietic B
progenitor I
cell I
line I
. O

To O
investigate O
the O
role O
of O
NF-M O
in O
hematopoietic B
cell I
lineage I
commitment O
, O
we O
constructed O
a O
conditional O
form O
of O
the O
protein O
by O
fusing O
it O
to O
the O
hormone O
binding O
domain O
of O
the O
human O
estrogen O
receptor O
. O

This O
construct O
was O
stably O
expressed O
in O
a O
multipotent B
progenitor I
cell I
line I
transformed O
by O
the O
Myb-Ets O
oncoprotein O
. O

We O
report O
here O
that O
both O
NF-M-dependent O
promoter O
constructs O
and O
resident O
genes O
could O
be O
activated O
by O
addition O
of O
beta-estradiol O
to O
the O
NF-M-estrogen B
receptor I
expressing I
progenitors I
. O

We O
investigated O
the O
ability O
of O
PRL O
and O
IL-2 O
to O
activate O
Stat O
proteins O
in O
different O
T B
cell I
lines I
. O

The O
DNA O
binding O
specificities O
, O
the O
reactivities O
toward O
Stat-specific O
antisera O
, O
and O
the O
mol O
wt O
of O
IL-2 O
-and O
PRL-induced O
DNA-binding O
proteins O
in O
Nb2 B
and I
C196 I
T I
cell I
lines I
were O
investigated O
. O

A O
comparison O
with O
the O
Stat O
proteins O
induced O
by O
interferon-gamma O
, O
PRL O
, O
and O
IL-6 O
in O
T47D B
mammary I
tumor I
cells I
was O
made O
. O

ETS1 O
transactivates O
the O
human O
GM-CSF O
promoter O
in O
Jurkat B
T I
cells I
stimulated O
with O
PMA O
and O
ionomycin O
. O

Other O
unidentified O
ETS-like O
factors O
present O
in O
Jurkat B
cells I
are O
also O
capable O
of O
binding O
GM5 O
. O

The O
hematopoietic O
transcription O
factor O
PU.1 O
is O
downregulated O
in O
human B
multiple I
myeloma I
cell I
lines I
. O

We O
have O
analyzed O
the O
expression O
and O
activity O
of O
PU.1 O
during O
human O
B-cell O
development O
using O
a O
panel O
of O
B-cell B
lines I
representing O
different O
stages O
of O
maturation O
, O
from O
early B
precursors I
to O
differentiated B
plasma I
cells I
. O

PU.1 O
mRNA O
expression O
and O
PU.1 O
DNA O
binding O
activity O
, O
as O
measured O
by O
Northern O
blot O
analysis O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
were O
evident O
in O
cell B
lines I
representing O
pro-B B
, I
pre-B I
, I
and I
mature I
B I
cells I
. O

We O
could O
also O
show O
Pu O
box O
-dependent O
transactivation O
of O
a O
reporter O
gene O
in O
transient O
transfections O
in O
these O
cell B
lines I
. O

In O
contrast O
, O
in O
a O
number O
of O
multiple B
myeloma I
cell I
lines I
, O
representing O
differentiated O
, O
plasma O
cell-like O
B O
cells O
, O
PU.1 O
DNA O
binding O
activity O
, O
mRNA O
expression O
, O
and O
Pu O
box O
-dependent O
transactivation O
were O
absent O
or O
detectable O
at O
a O
very O
low O
level O
. O

In O
lymphoblastoid B
cell I
lines I
, O
which O
exemplify O
an O
intermediate O
stage O
of O
B-cell O
differentiation O
, O
a O
reduced O
expression O
and O
activity O
were O
observed O
. O

The O
findings O
in O
the O
human B
multiple I
myeloma I
cell I
lines I
represent O
the O
first O
examples O
of O
B O
cells O
with O
downregulated O
PU.1 O
expression O
and O
apparently O
contradict O
observations O
in O
the O
murine O
system O
in O
which O
PU.1 O
is O
expressed O
and O
active O
in O
plasmacytoma B
cell I
lines I
. O

At O
present O
, O
it O
is O
unclear O
whether O
the O
lack O
of O
PU.1 O
expression O
and O
activity O
in O
human B
multiple I
myeloma I
cell I
lines I
represents O
a O
malignancy-associated O
defect O
in O
these O
cells O
or O
exemplifies O
a O
normal O
developmental O
regulation O
in O
terminally O
differentiated O
B O
cells O
. O

CD4+ B
macrophages I
in O
tissues O
such O
as O
lung O
, O
skin O
, O
and O
lymph O
nodes O
, O
promyelocytic O
cells O
in O
bone O
marrow O
, O
and O
peripheral O
blood O
monocytes O
serve O
as O
important O
targets O
and O
reservoirs O
for O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
replication O
. O

In O
response O
to O
secondary O
pathogenic O
infections O
or O
antigenic O
challenge O
, O
cytokine O
gene O
expression O
is O
rapidly O
induced O
, O
enhanced O
, O
and O
sustained O
over O
prolonged O
periods O
in O
HIV-1-infected B
myeloid I
cells I
compared O
with O
uninfected O
cells O
. O

CEM-ICR B
27 I
leukemic I
lymphoblasts I
, O
a O
clone O
of O
CEM B
cells I
which O
lack O
functional O
glucocorticoid O
receptors O
and O
therefore O
are O
neither O
lysed O
by O
dexamethasone O
nor O
capable O
of O
showing O
glutamine O
synthetase O
induction O
, O
were O
provided O
with O
steroid O
receptors O
by O
DNA O
transfections O
of O
various O
receptor O
gene O
constructs O
. O

We O
measured O
steroid O
mediated O
lysis O
, O
receptor O
number O
and O
induction O
of O
glutamine O
synthetase O
in O
the O
transfected B
cells I
. O

Our O
results O
provide O
evidence O
that O
the O
lysis O
mechanism O
in O
the O
ICR27 B
lymphoblasts I
is O
restored O
when O
functional O
receptor O
number O
is O
restored O
. O

We O
prepared O
nuclear O
extracts O
from O
two O
human B
B I
cell I
lines I
in O
which O
increased O
intracellular O
free O
calcium O
levels O
correlated O
with O
increased O
phosphorylation O
of O
the O
Ets-1 O
protein O
. O

CD30 O
ligation O
induces O
nuclear O
factor-kappa O
B O
activation O
in O
human B
T I
cell I
lines I
. O

In O
this O
report O
, O
we O
show O
that O
following O
incubation O
of O
L540 B
cells I
( O
Hodgkin B
's I
disease-derived I
, I
T I
cell-like I
, I
CD30+ I
cells I
) O
with O
the O
agonistic O
anti-CD30 O
monoclonal O
antibodies O
( O
mAb O
) O
M44 O
and O
M67 O
, O
two O
nuclear O
factor O
( O
NF O
) O
-kappa O
B O
DNA O
binding O
activities O
were O
induced O
in O
nuclear O
extracts O
, O
as O
determined O
in O
gel O
retardation O
assays O
. O

Moreover O
, O
in O
human B
T I
helper I
( I
Th I
) I
clones I
functionally O
characterized O
as O
being O
of O
the O
type O
0 O
, O
type O
1 O
and O
type O
2 O
( O
28 O
% O
, O
< O
1 O
% O
und O
93 O
% O
CD30+ O
, O
respectively O
) O
, O
the O
extent O
of O
CD30 O
-mediated O
NF-kappa O
B O
activation O
correlated O
with O
the O
proportion O
of O
CD30+ B
cells I
. O

Activation O
of O
individual O
CD4+ B
T I
cells I
results O
in O
differential O
lymphokine O
expression O
: O
interleukin O
2 O
( O
IL-2 O
) O
is O
preferentially O
produced O
by O
T B
helper I
type I
1 I
( I
TH1 I
) I
cells I
, O
which O
are O
involved O
in O
cell-mediated O
immune O
responses O
, O
whereas O
IL-4 O
is O
synthesized O
by O
TH2 B
cells I
, O
which O
are O
essential O
for O
humoral O
immunity O
. O

However O
, O
while O
IL2 O
expression O
requires O
the O
contribution O
of O
Ca O
( O
2+ O
) O
- O
and O
protein O
kinase O
C O
-dependent O
signals O
, O
we O
report O
that O
activation O
of O
human O
IL4 O
transcription O
through O
the O
Ca O
( O
2+ O
) O
-dependent O
pathway O
is O
diminished O
by O
protein O
kinase O
C O
stimulation O
in O
Jurkat B
T I
cells I
. O

Human O
IL4 O
promoter O
-mediated O
transcription O
is O
downregulated O
in O
Jurkat B
cells I
stimulated O
with O
the O
NF-kappa O
B-activating O
cytokine O
tumor O
necrosis O
factor O
alpha O
and O
suppressed O
in O
RelA-overexpressing B
cells I
. O

Thus O
, O
competition O
between O
two O
general O
transcriptional O
activators O
, O
RelA O
and O
NF-ATp O
, O
mediates O
the O
inhibitory O
effect O
of O
protein O
kinase O
C O
stimulation O
on O
IL4 O
expression O
and O
may O
contribute O
to O
differential O
gene O
expression O
in O
TH B
cells I
. O

We O
used O
mononuclear B
cell I
priming I
cultures I
and O
inflammatory O
synovial O
fluids O
( O
SFs O
) O
derived O
from O
arthritis O
patients O
to O
examine O
the O
regulation O
of O
cytokine O
production O
and O
STAT O
activity O
by O
an O
inflammatory O
synovial O
microenvironment O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement O
receptors O
CR1 O
( O
CD35 O
) O
and O
CR3 O
( O
CD11b/CD18 O
) O
enhances O
viral O
replication O
in O
HIV-infected B
human I
monocytic I
cells I
. O

Monocytic B
cell I
lines I
and O
normal O
peripheral O
blood O
monocytes O
were O
infected O
with O
HIV-1 O
in O
vitro O
and O
cultured O
in O
the O
presence O
or O
absence O
of O
F O
( O
ab O
' O
) O
2 O
fragments O
of O
monoclonal O
anti-CR1 O
or O
anti-CR3 O
Abs O
or O
with O
C3 O
fragments O
. O

Stimulation O
of O
CR1 O
or O
CR3 O
induces O
a O
two- O
to O
fourfold O
increase O
in O
the O
amount O
of O
cell-associated O
and O
released O
p24 O
Ag O
in O
cell B
cultures I
that O
was O
equivalent O
to O
that O
observed O
in O
control B
cultures I
triggered O
with O
LPS O
. O

To O
investigate O
the O
mechanisms O
accounting O
for O
the O
impaired O
responses O
to O
gamma O
interferon O
, O
a O
model O
system O
for O
examining O
overall O
changes O
in O
protein O
tyrosine O
phosphorylation O
, O
activation O
of O
Jak1 O
and O
Jak2 O
and O
phosphorylation O
of O
Stat1 O
was O
developed O
in O
phorbol B
12-myristate I
13-acetate-differentiated I
U-937 I
cells I
. O

Jak1 O
, O
Jak2 O
, O
and O
Stat1 O
were O
immunoprecipitated O
from O
control O
and O
interferon-treated B
cells I
, O
and O
tyrosine O
phosphorylation O
of O
these O
proteins O
, O
detected O
by O
antiphosphotyrosine O
immunoblotting O
was O
used O
to O
measured O
their O
activation O
. O

Tyrosine O
phosphorylation O
of O
Jak1 O
, O
Jak2 O
, O
and O
Stat1 O
increased O
markedly O
, O
in O
a O
dose-dependent O
manner O
, O
in O
U-937 B
cells I
incubated O
with O
gamma O
interferon O
. O

Results O
similar O
to O
those O
observed O
with O
U-937 B
cells I
were O
also O
obtained O
with O
human O
peripheral O
blood O
monocytes O
. O

Purified O
MAR-BP1 O
migrates O
as O
a O
33-kDa O
protein O
, O
and O
it O
can O
be O
found O
in O
nuclear O
matrix O
preparations O
from O
a O
number O
of O
different O
types O
of O
lymphoid B
cell I
lines I
. O

C/EBP O
alpha O
is O
the O
major O
CCAAT/enhancer-binding O
protein O
( O
C/EBP O
) O
form O
binding O
to O
this O
site O
in O
nuclear O
extracts O
of O
U937 B
cells I
. O

Constitutive O
activation O
of O
different O
Jak O
tyrosine O
kinases O
in O
human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV-1 O
) O
tax O
protein O
or O
virus-transformed B
cells I
. O

Constitutive O
tyrosine O
phosphorylation O
of O
a O
130-kD O
protein O
( O
s O
) O
was O
observed O
in O
the O
tax O
transformed B
fibroblast I
B I
line I
and O
in O
HTLV-1 B
transformed I
human I
lymphoid I
lines I
, O
but O
not O
in O
thymocytes O
from O
Thy-tax O
transgenic O
mice O
. O

Phosphotyrosine O
immunoprecipitation O
followed O
by O
Western O
blot O
analysis O
with O
a O
set O
of O
Jak O
kinase O
specific O
antibodies O
, O
identified O
p130 O
as O
Jak2 O
in O
the O
tax O
transformed O
mouse B
fibroblastic I
cell I
line I
and O
Jak3 O
in O
HTLV-1 B
transformed I
human I
T I
cell I
lines I
. O

Phosphorylation O
of O
Jak2 O
in O
tax B
transformed I
cells I
resulted O
from O
high O
expression O
of O
IL-6 O
. O

Tyrosine O
phosphorylation O
of O
this O
protein O
could O
also O
be O
induced O
in O
Balb/c3T3 B
cells I
using O
a O
supernatant O
from O
the O
B B
line I
, O
which O
was O
associated O
with O
induction O
of O
cell O
proliferation O
. O

Regulation O
of O
c-jun O
mRNA O
expression O
by O
hydroxyurea O
in O
human B
K562 I
cells I
during O
erythroid O
differentiation O
[ O
published O
erratum O
appears O
in O
Biochim O
Biophys O
Acta O
1995 O
Dec O
27 O
; O
1264 O
( O
3 O
) O
: O
409 O
] O

To O
further O
understand O
its O
mechanism O
of O
action O
, O
we O
investigated O
the O
effects O
of O
HU O
on O
regulation O
of O
c-jun O
expression O
prior O
to O
the O
onset O
of O
erythroid O
differentiation O
of O
K562 B
cells I
. O

In O
addition O
, O
the O
level O
of O
jun O
protein O
was O
elevated O
by O
2 O
to O
5-fold O
within O
4 O
h O
in O
HU B
treated I
cells I
. O

Oncogenicity O
of O
human B
papillomavirus- I
or I
adenovirus-transformed I
cells I
correlates O
with O
resistance O
to O
lysis O
by O
natural O
killer O
cells O
. O

As O
one O
test O
of O
this O
hypothesis O
, O
we O
compared O
the O
abilities O
of O
E1A O
-and O
E7 O
-expressing O
human B
fibroblastic I
or I
keratinocyte-derived I
human I
cells I
to O
be O
selectively O
killed O
by O
either O
unstimulated O
or O
interferon B
( I
IFN I
) I
-activated I
NK I
cells I
. O

Cells O
expressing O
the O
E1A O
oncoprotein O
were O
selectively O
killed O
by O
unstimulated B
NK I
cells I
, O
while O
the O
same O
parental O
cells O
but O
expressing O
the O
HPV O
type O
16 O
( O
HPV-16 O
) O
or O
HPV-18 O
E7 O
oncoprotein O
were O
resistant O
to O
NK O
cell O
lysis O
. O

The O
ability O
of O
IFN-activated B
NK I
cells I
to O
selectively O
kill O
virally O
transformed O
cells O
depends O
on O
IFN O
's O
ability O
to O
induce O
resistance O
to O
NK O
cell O
lysis O
in O
normal O
( O
i.e. O
, O
non-viral B
oncogene-expressing I
) O
but O
not O
virally B
transformed I
cells I
. O

E1A O
blocked O
IFN O
's O
induction O
of O
cytolytic O
resistance O
, O
resulting O
in O
the O
selective O
lysis O
of O
adenovirus-transformed B
cells I
by O
IFN-activated B
NK I
cells I
. O

The O
extent O
of O
IFN O
-induced O
NK O
cell O
killing O
of O
E1A-expressing B
cells I
was O
proportional O
to O
the O
level O
of O
E1A O
expression O
and O
correlated O
with O
the O
ability O
of O
E1A O
to O
block O
IFN O
-stimulated O
gene O
expression O
in O
target O
cells O
. O

In O
contrast O
, O
E7 O
blocked O
neither O
IFN O
-stimulated O
gene O
expression O
nor O
IFN O
's O
induction O
of O
cytolytic O
resistance O
, O
thereby O
precluding O
the O
selective O
lysis O
of O
HPV-transformed B
cells I
by O
IFN-activated B
NK I
cells I
. O

The O
Ca O
( O
2+ O
) O
-dependent O
phosphatase O
calcineurin O
, O
a O
target O
of O
FK506 O
and O
CsA O
, O
synergizes O
with O
PKC O
-induced O
activation O
of O
nuclear O
factor O
( O
NF O
) O
-kappa O
B O
in O
T B
cell I
lines I
. O

While O
this O
synergy O
is O
present O
in O
other O
cell O
types O
, O
in O
the O
monocytic B
cell I
line I
U937 I
calcineurin O
is O
also O
sufficient O
to O
activate O
NF-kappa O
B O
. O

While O
PKC O
-dependent O
pathways O
sequentially O
result O
in O
the O
phosphorylation O
and O
in O
an O
incomplete O
degradation O
of O
IkB O
alpha O
in O
T B
cell I
lines I
, O
co-activation O
of O
Ca O
( O
2+ O
) O
-dependent O
pathways O
accelerates O
the O
rate O
of O
IkB O
alpha O
phosphorylation O
and O
results O
in O
its O
complete O
degradation O
. O

Activation O
of O
Ca O
( O
2+ O
) O
-dependent O
pathways O
alone O
do O
not O
result O
in O
the O
phosphorylation O
and/or O
degradation O
of O
IkB O
alpha O
in O
Jurkat B
T I
or O
in O
U937 B
cells I
. O

They O
inhibit O
synthesis O
of O
almost O
all O
known O
cytokines O
and O
of O
several O
cell O
surface O
molecules O
required O
for O
immune O
function O
, O
but O
the O
mechanism O
underlying O
this O
activity O
has O
been O
unclear. O
Here O
it O
is O
shown O
that O
glucocorticoids O
are O
potent O
inhibitors O
of O
nuclear O
factor O
kappa O
B O
( O
NF-kappa O
B O
) O
activation O
in O
mice O
and O
cultured B
cells I
. O

We O
report O
here O
that O
1 O
, O
25 O
( O
OH O
) O
2D3-mediated O
repression O
in O
Jurkat B
cells I
is O
cycloheximide O
resistant O
, O
suggesting O
that O
it O
is O
a O
direct O
transcriptional O
repressive O
effect O
on O
IL-2 O
expression O
by O
the O
vitamin O
D3 O
receptor O
( O
VDR O
) O
. O

We O
therefore O
examined O
vitamin O
D3-mediated O
repression O
of O
activated O
IL-2 O
expression O
by O
cotransfecting O
Jurkat B
cells I
with O
IL-2 O
promoter/reporter O
constructs O
and O
a O
VDR O
overexpression O
vector O
and O
by O
DNA O
binding O
. O

We O
demonstrate O
in O
this O
report O
that O
the O
5 O
' O
flanking O
DNA O
of O
the O
15-lox O
gene O
contains O
sequences O
which O
down-regulate O
its O
activity O
in O
a O
variety O
of O
non-erythroid B
cell I
lines I
but O
not O
in O
two O
erythroid B
cell I
lines I
. O

Phosphorylation O
of O
the O
transcription O
factor O
NFATp O
inhibits O
its O
DNA O
binding O
activity O
in O
cyclosporin B
A-treated I
human I
B I
and O
T O
cells O
. O

Here O
we O
report O
that O
CsA O
treatment O
of O
Raji B
B I
and O
Jurkat B
T I
cell I
lines I
yields O
a O
phosphorylated O
form O
of O
NFATp O
that O
is O
inhibited O
in O
DNA-binding O
and O
in O
its O
ability O
to O
form O
an O
NFAT O
complex O
with O
Fos O
and O
Jun O
. O

We O
examined O
by O
northern O
hybridization O
the O
expression O
of O
Id2 O
and O
Id3 O
mRNA O
in O
human B
leukemia/lymphoma I
lines I
and O
patient O
samples O
, O
as O
well O
as O
resting O
and O
activated B
normal I
human I
lymphocytes I
from O
peripheral O
blood O
( O
PBL O
) O
. O

The O
Id2 O
mRNA O
was O
abundantly O
expressed O
in O
5/12 B
T-cell I
and O
3/4 B
B-cell I
lines I
, O
and O
Id3 O
mRNA O
was O
detected O
in O
4/12 B
T-cell I
and O
3/4 B
B-cell I
lines I
. O

Interestingly O
, O
Id2 O
, O
but O
not O
Id3 O
, O
mRNA O
was O
strongly O
expressed O
in O
4/5 B
T-cell I
lines I
infected O
with O
human O
T-cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
( O
ATL-1k B
, O
MT-2 B
, O
S-LB1 B
) O
and O
type O
II O
( O
Mo B
) O
. O

Another O
unexpected O
finding O
was O
that O
T-cell O
leukemias O
and O
T-cell B
lines I
often O
expressed O
either O
Id2 O
or O
Id3 O
mRNA O
. O

Here O
, O
we O
report O
that O
a O
family O
of O
anti-inflammatory O
agents O
, O
known O
as O
the O
salicylates O
, O
inhibited O
LPS O
induction O
of O
TF O
activity O
and O
TF O
gene O
transcription O
in O
human O
monocytes O
and O
monocytic B
THP-1 I
cells I
at O
clinically O
relevant O
doses O
. O

Antigen O
recognition O
stimulates O
limited O
proliferation O
, O
whereas O
infection O
with O
Epstein-Barr O
virus O
( O
EBV O
) O
results O
in O
continual O
proliferation O
and O
the O
outgrowth O
of O
immortal B
cell I
lines I
. O

Northern O
blot O
analysis O
revealed O
that O
BLR2 O
mRNA O
could O
be O
highly O
stimulated O
in O
mitogen- B
and I
anti-CD3-treated I
peripheral I
blood I
lymphocytes I
. O

BLR2-specific O
mRNA O
could O
be O
detected O
in O
all O
Epstein-Barr B
virus I
positive I
B I
cell I
lines I
. O

We O
show O
that O
transcription O
of O
the O
BLR2 O
gene O
could O
be O
specifically O
induced O
in O
Epstein-Barr B
virus I
negative I
BL I
41 I
cells I
via O
estrogen-mediated O
activation O
of O
Epstein-Barr O
virus O
nuclear O
antigen O
2 O
, O
a O
key O
regulator O
of O
viral O
and O
cellular O
genes O
in O
immortalized B
B I
cells I
. O

In O
both O
transiently B
cotransfected I
human I
cells I
and O
stable O
chromatin-integrated B
yeast I
cells I
, O
c-Myb O
strongly O
transactivated O
reporter O
constructs O
that O
contained O
polymerized O
core O
sequences O
. O

Point O
mutation O
of O
the O
c-Myb O
site O
within O
the O
intact O
2.3-kb O
LCR O
severely O
attenuated O
enhancer O
activity O
in O
transfections O
and O
LCR O
activity O
in O
transgenic B
thymocytes I
. O

In O
unstimulated O
cells O
which O
do O
not O
secrete O
IL-2 O
, O
only O
Sp1 O
binds O
to O
this O
region O
, O
while O
in O
stimulated B
IL-2 I
secreting I
cells I
the O
inducible O
EGR-1 O
protein O
recognizes O
this O
element O
. O

In O
Jurkat B
T I
cells I
, O
the O
ZIP O
site O
serves O
as O
an O
activator O
for O
IL-2 O
gene O
expression O
, O
and O
a O
combination O
of O
ZIP O
and O
NFAT O
binding O
sites O
is O
required O
for O
maximal O
IL-2 O
promoter O
activity O
. O

First O
, O
we O
show O
that O
mutations O
in O
the O
LEF-1-binding O
site O
inhibit O
the O
activity O
of O
multimerized O
copies O
of O
the O
HIV-1 O
enhancer O
in O
Jurkat B
T I
cells I
, O
and O
that O
LEF-1/GAL4 O
can O
activate O
a O
GAL4-substituted O
HIV-1 O
enhancer O
80- O
to O
100-fold O
in O
vivo O
. O

Activation O
of O
CD4 O
positive O
T O
cells O
is O
a O
primary O
requirement O
for O
human O
immunodeficiency O
virus O
( O
HIV O
) O
entry O
, O
efficient O
HIV O
replication O
, O
and O
progression O
to O
AIDS O
, O
Utilizing O
CD4 B
positive I
T I
cell I
lines I
and O
purified O
T O
cells O
from O
normal O
individuals O
, O
we O
have O
demonstrated O
that O
native O
envelope O
glycoproteins O
of O
HIV O
, O
gp O
160 O
, O
can O
induce O
activation O
of O
transcription O
factor O
, O
activated O
protein-1 O
( O
AP-1 O
) O
. O

The O
stimulatory O
effects O
of O
gp160 O
are O
mediated O
through O
the O
CD4 O
molecule O
, O
since O
treatment O
of O
gp160 O
with O
soluble O
CD4-IgG O
abrogates O
its O
activity O
, O
and O
CD4 B
negative I
T I
cell I
lines I
fail O
to O
be O
stimulated O
with O
gp160 O
. O

